Preparing your results

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Buprenorphine tapering schedule and illicit opioid use.

AIMS: To compare the effects of a short or long taper schedule after buprenorphine stabilization on participant outcomes as measured by opioid-free urine tests at the end of each taper period. DESIGN: This multi-site study sponsored by Clinical Trials Network (CTN, a branch of the US National Institute on Drug Abuse) was conducted from 2003 to 2005 to compare two taper conditions (7 days and 28 days). Data were collected at weekly clinic visits to the end of the taper periods, and at 1-month and 3-month post-taper follow-up visits. SETTING: Eleven out-patient treatment programs in 10 US cities. INTERVENTION: Non-blinded dosing with Suboxone during the 1-month stabilization phase included 3 weeks of flexible dosing as determined appropriate by the study physicians. A fixed dose was required for the final week before beginning the taper phase. MEASUREMENTS: The percentage of participants in each taper group providing urine samples free of illicit opioids at the end of the taper and at follow-up. FINDINGS: At the end of the taper, 44% of the 7-day taper group (n = 255) provided opioid-free urine specimens compared to 30% of the 28-day taper group (n = 261; P = 0.0007). There were no differences at the 1-month and 3-month follow-ups (7-day = 18% and 12%; 28-day = 18% and 13%, 1 month and 3 months, respectively). CONCLUSION: For individuals terminating buprenorphine pharmacotherapy for opioid dependence, there appears to be no advantage in prolonging the duration of taper.

Pubmed ID: 19149822


  • Ling W
  • Hillhouse M
  • Domier C
  • Doraimani G
  • Hunter J
  • Thomas C
  • Jenkins J
  • Hasson A
  • Annon J
  • Saxon A
  • Selzer J
  • Boverman J
  • Bilangi R


Addiction (Abingdon, England)

Publication Data

February 19, 2009

Associated Grants

  • Agency: NIDA NIH HHS, Id: U10 DA 013035
  • Agency: NIDA NIH HHS, Id: U10 DA 013036
  • Agency: NIDA NIH HHS, Id: U10 DA 013038
  • Agency: NIDA NIH HHS, Id: U10 DA 013046
  • Agency: NIDA NIH HHS, Id: U10 DA013045
  • Agency: NIDA NIH HHS, Id: U10 DA013045-12
  • Agency: NIDA NIH HHS, Id: U10 DA013714
  • Agency: NIDA NIH HHS, Id: U10 DA13045
  • Agency: NIDA NIH HHS, Id: U10 DA13716
  • Agency: NIDA NIH HHS, Id: U10DA13034
  • Agency: NIDA NIH HHS, Id: U10DA13711

Mesh Terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Buprenorphine
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Middle Aged
  • Naloxone
  • Narcotic Antagonists
  • Opioid-Related Disorders
  • Substance Abuse Detection
  • Substance Withdrawal Syndrome
  • Time Factors
  • United States
  • Young Adult